A Phase 3, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Acute Treatment of Anxiety in Social Anxiety Disorder (AFFIRM-1)
Positive Results Achieved in a Phase 2b, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Treatment of PTSD (ATTUNE)
Subjective Units of Distress Scale (SUDS) is a psychometrically valid and reliable outcome measure for the assessment of anxiety in social anxiety disorder (SAD) clinical trials
Development of an Improved Oral Tablet Formulation of BNC210, a Negative Allosteric Modulator of the α7 nAChR, Suitable for Evaluation as an Acute Treatment for Social Anxiety Disorder